SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.410
-0.070 (-2.01%)
Jun 3, 2026, 2:32 PM EDT - Market open
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
239.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Compugen | 72.66M |
| Coherus Oncology | 46.88M |
| Foghorn Therapeutics | 28.22M |
| LENZ Therapeutics | 20.99M |
| Caribou Biosciences | 11.20M |
| Adagene | 7.67M |
| Entrada Therapeutics | 5.74M |
SABS News
- 5 days ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire
- 12 days ago - SAB Biotherapeutics initiated with a Buy at Citi - TheFly
- 14 days ago - SAB Biotherapeutics initiated with a Buy at Jefferies - TheFly
- 21 days ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 22 days ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 22 days ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 22 days ago - SAB Biotherapeutics Earnings release: Q1 2026 - Filings
- 22 days ago - SAB Biotherapeutics Quarterly report: Q1 2026 - Filings